Novavax Licenses Recombinant VLP Influenza Vaccine to LG Life Sciences for South Korea and Other Countries.

The article reports that Novavax Inc. signed an agreement with LG Life Sciences Ltd. (LGLS) to license its recombinant virus-like-particle (VLP) influenza vaccine technology. The agreement enables LGLS to manufacture, develop and market influenza vaccines using the VLP technology in South Korea and other emerging countries. Furthermore, the agreement will provide LGLS the responsibility to fund clinical development and licensure of influenza VLP vaccines in South Korea.